Bayer outlook revised to negative by S&P on litigation risks
NegativeFinancial Markets

Bayer's outlook has been revised to negative by S&P due to ongoing litigation risks, which raises concerns about the company's future financial stability. This change reflects the increasing scrutiny and potential liabilities Bayer faces, particularly related to its past product controversies. Investors and stakeholders should pay close attention to how these legal challenges may impact Bayer's operations and market position.
— Curated by the World Pulse Now AI Editorial System